Atlas Trials

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Clinical trial NCT06062641 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06062641
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory B-cell Lymphoma
Start date
2023-10-30
Primary completion
2024-04-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.